Integrating ctDNA-based ESR1m monitoring into first-line care for ER+, HER2− advanced breast cancer: a consensus workflow
Abstract Circulating tumor DNA (ctDNA) is an emerging tool in precision oncology that enables noninvasive tumor profiling, detection of minimal residual disease, and treatment monitoring. Furthermore, routine ctDNA analyses offer the potential to support more personalized and dynamic cancer care. In advanced breast can...